BIOC Stock Overview
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Biocept, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.02 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$0.80 |
| Beta | 0.59 |
| 1 Month Change | -38.92% |
| 3 Month Change | -13.56% |
| 1 Year Change | -95.67% |
| 3 Year Change | -99.28% |
| 5 Year Change | -99.85% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth
Apr 17
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position
Nov 23Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings
Aug 19Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being
Jul 03Biocept and CLEARED4 ink collaboration agreement
Jun 09Biocept enters COVID-19 testing partnership
Apr 28Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain
Mar 13We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate
Jan 26
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?
Dec 22Biocept's assays viable and sensitive for detecting tumor cells and biomarkers
Nov 20Biocept +4% on COVID-19 testing update
Nov 12Shareholder Returns
| BIOC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.8% | -4.2% | -3.7% |
| 1Y | -95.7% | -2.0% | 20.5% |
Return vs Industry: BIOC underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: BIOC underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| BIOC volatility | |
|---|---|
| BIOC Average Weekly Movement | 20.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOC's share price has been volatile over the past 3 months.
Volatility Over Time: BIOC's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 50 | Antonino Morales | biocept.com |
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.
Biocept, Inc. Fundamentals Summary
| BIOC fundamental statistics | |
|---|---|
| Market cap | US$2.68m |
| Earnings (TTM) | -US$30.61m |
| Revenue (TTM) | US$1.36m |
2.0x
P/S Ratio-0.1x
P/E RatioIs BIOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOC income statement (TTM) | |
|---|---|
| Revenue | US$1.36m |
| Cost of Revenue | US$15.66m |
| Gross Profit | -US$14.30m |
| Other Expenses | US$16.30m |
| Earnings | -US$30.61m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.66 |
| Gross Margin | -1,054.09% |
| Net Profit Margin | -2,255.49% |
| Debt/Equity Ratio | 181.4% |
How did BIOC perform over the long term?
See historical performance and comparison